2023-509092-16-00招募中2 期
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
Akershus University Hospital1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2024年10月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) based on measurements of Health-related quality of life (HRQoL) and total costs of treatment and follow-up
研究概览
简要总结
To evaluate the cost-effectiveness of a precision therapy strategy compared with standard treatment in elderly unfit patients with AML, MDS or CMML-2.
入排标准
- 年龄范围
- 65 years 至 65+ years（65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Patients with: a. a newly or recurrent/refractory diagnosis of AML and related precursor neoplasms according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease and therapy-related AML ), or b. acute leukemias of ambiguous lineage according to WHO 2016 or c. a newly or recurrent diagnosis of myelodysplastic syndrome (MDS) with IPSS-R > 4.5.1 or d. a newly or recurrent diagnosis of chronic myelomonocytic leukemia with 10-19% blasts or blast equivalents in the bone-marrow (CMML-2).
- •Patients 60 years and older.
- •Patients must NOT be eligible for intensive chemotherapy or allogeneic stem cell therapy
- •WBC ≤ 30 x109/L (prior hydroxyurea allowed for a maximum of 14 days, stopped before start of treatment)
- •Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values: a. Serum creatinine ≤ 2.5 mg/dL (≤ 221.7 μmol/L), unless considered AML-related b. Serum bilirubin ≤ 2.5 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert’s syndrome c. Alanine transaminase (ALT) ≤ 2.5 x ULN, unless considered AML-related
- •WHO performance status 0, 1 or 2 for subjects ≥ 75 years of age OR 0 to 3 for subjects ≥ 60 to 74 years of age.
- •Signed Informed Consent
- •Male Subjects Only: Male subjects who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice contraception with condom. Male subjects must agree to refrain from sperm donation from initial study drug administration until at least 90 days after the last dose of study drug. If the patient is randomized to a targeted drug where the SPC recommends contraception more than 90 days after last dose, the SPC recommendation should be followed.
排除标准
- •Acute promyelocytic leukemia.
- •Patients who do not understand the Written Informed Consent (e.g., language problems)
- •Current concomitant chemotherapy, radiation therapy, or immunotherapy for other malignancies; other than hydroxyurea.
- •Subject is known to be positive for HIV (HIV testing is not required).
- •Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required). Subjects with serologic evidence of prior vaccination to HBV [ie. HBs Ag-, and anti-HBs+] may participate.
- •Subject has a malabsorption syndrome or other condition that precludes enteral route of administration.
- •AML with favourable cytogenetic or genetic changes in patients who are fit for intensive chemotherapy. Favourable genetics are: t(8;21)(q22;q22.1); RUNX1-RUNX1T1; inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11; mutated NPM1 without FLT3-ITD or with FLT3-ITDlow†; Biallelic mutated CEBPA.
- •Patients who previously were included in the Palm-study.
- •Patients where it is not possible to get bone-marrow for NGS, i.e., “dry tap”.
- •Blast crisis of chronic myeloid leukemia.
- •Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.)
- •Cardiac dysfunction as defined by: a. Unstable angina or b. New York Heart Association Class ≥
- •Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or angina pain or c. Unstable cardiac arrhythmias
- •Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance with the study protocol and follow-up schedule.
- •Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
结局指标
主要结局
Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) based on measurements of Health-related quality of life (HRQoL) and total costs of treatment and follow-up
Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) based on measurements of Health-related quality of life (HRQoL) and total costs of treatment and follow-up
次要结局
未报告次要终点
研究者
Anders Erik Astrup Dahm
Scientific
Akershus University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (PM-CARE). Single arm, multicenter phase II study investigating the efficacy and safety of a novel therapeutic scheme in patients with unresectable CholAngiocarcinoma; RadioEmbolization in combination with CisGem and Durvalumab (MEDI4736)2024-516498-57-00Ospedale San Raffaele S.r.l.33
招募中
4 期
LOW DOse vs standard dose and administration TIme in near-infrared fluorescence cholangiography during laparoscopic cholecystectomy: a randomised clinical trial.2025-522535-33-00Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon122
招募中
4 期
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDERheumatoid Arthritis2024-516704-41-00Les Hopitaux Universitaires De Strasbourg270
招募中
2 期
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment2024-518069-89-00Centr Georges Francois Leclerc230
招募中
2 期
Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab or Cemiplimab combined with chemotherapy according to levels of tumor DNA circulating in the blood2024-518812-38-00Fundacion GECP63